162 related articles for article (PubMed ID: 35862569)
1. Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review.
Plumptre IR; Said JT; Sun T; Larocca C; Virgen CA; Kupper TS; Fisher DC; Devlin PM; Elco CP; Song JS; LeBoeuf NR
Leuk Lymphoma; 2022 Dec; 63(12):2832-2846. PubMed ID: 35862569
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous CD4
Plumptre IR; Said JT; Sheu Song J; Corey K; LeBoeuf NR
Pediatr Blood Cancer; 2022 Sep; 69(9):e29862. PubMed ID: 35730956
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder: Report of a case and review of the literature.
Keeling BH; Gavino ACP; Admirand J; Soldano AC
J Cutan Pathol; 2017 Nov; 44(11):944-947. PubMed ID: 28749588
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Spectrum of Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder: An Updated Systematic Literature Review and Case Series.
Surmanowicz P; Doherty S; Sivanand A; Parvinnejad N; Deschenes J; Schneider M; Hardin J; Gniadecki R
Dermatology; 2021; 237(4):618-628. PubMed ID: 33326960
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category.
Williams VL; Torres-Cabala CA; Duvic M
Am J Clin Dermatol; 2011 Dec; 12(6):389-401. PubMed ID: 21863906
[TBL] [Abstract][Full Text] [Related]
6. Primary Cutaneous CD4
Maurelli M; Colato C; Gisondi P; Girolomoni G
J Cutan Med Surg; 2017; 21(6):502-506. PubMed ID: 28605998
[TBL] [Abstract][Full Text] [Related]
7. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature.
James E; Sokhn JG; Gibson JF; Carlson K; Subtil A; Girardi M; Wilson LD; Foss F
Leuk Lymphoma; 2015 Apr; 56(4):951-7. PubMed ID: 24996443
[TBL] [Abstract][Full Text] [Related]
8. CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.
Richter J; Oschlies I; Kock K; Wüseke T; Haag J; Koch K; Klapper W
J Pathol; 2024 Feb; 262(2):189-197. PubMed ID: 37933684
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up and management of small and medium-sized CD4
Virmani P; Jawed S; Myskowski PL; Horwitz S; Skripnik Lucas A; Moskowitz A; Pulitzer M; Zain J; Rosen ST; Querfeld C
Int J Dermatol; 2016 Nov; 55(11):1248-1254. PubMed ID: 27369070
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder in a young woman.
Leeolou MC; Young PA; Saleem A; Narala S; Bae GH
Dermatol Online J; 2022 Dec; 28(6):. PubMed ID: 36809093
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation.
Kim EJ; Aria AB; Wilmas K; Lewis DJ; Torres-Cabala CA; Nunez C; Dabaja BS; Duvic M
Pediatr Dermatol; 2019 Jan; 36(1):e23-e26. PubMed ID: 30548331
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma.
Alberti-Violetti S; Torres-Cabala CA; Talpur R; Corti L; Fanoni D; Venegoni L; Berti E; Duvic M
J Cutan Pathol; 2016 Dec; 43(12):1121-1130. PubMed ID: 27550169
[TBL] [Abstract][Full Text] [Related]
13. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease.
Magro CM; Olson LC; Fulmer CG
Ann Diagn Pathol; 2017 Oct; 30():52-58. PubMed ID: 28965629
[TBL] [Abstract][Full Text] [Related]
14. Case for diagnosis. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.
Valentim FO; Oliveira CC; Miot HA
An Bras Dermatol; 2019; 94(1):99-101. PubMed ID: 30726474
[TBL] [Abstract][Full Text] [Related]
15. The development of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder at the site of a melanoma excision scar.
Aria AB; Wilmas K; Kim EJ; Aung PP; Duvic M
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677830
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder: Where do we stand? A systematic review.
Salah E
J Dtsch Dermatol Ges; 2019 Feb; 17(2):123-136. PubMed ID: 30506921
[TBL] [Abstract][Full Text] [Related]
17. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma.
Cetinözman F; Jansen PM; Willemze R
Am J Surg Pathol; 2012 Jan; 36(1):109-16. PubMed ID: 21989349
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment.
Gru AA; Wick MR; Eid M
Semin Cutan Med Surg; 2018 Mar; 37(1):39-48. PubMed ID: 29719019
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a case with multiple tumors.
Sarac E; Demirkesen C
An Bras Dermatol; 2023; 98(5):720-722. PubMed ID: 37225627
[No Abstract] [Full Text] [Related]
20. Cyclin D1 expression, cell proliferation, and clonal persistence characterize primary cutaneous CD4
Oschlies I; Kock K; Wüseke T; Richter J; Koch K; Wehkamp U; Klapper W
Histopathology; 2023 Feb; 82(3):485-494. PubMed ID: 36341542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]